6-K ·Filed Apr 16, 2026
Notable filing: 6-K
Actionable Insight ▲ Bullish
Review the filing for details
Final — all horizons settled through T+60d
RDPTF ▼ -50.00% at T+60d
LONG call ✗ call lost -50.00% · α vs SPY -57.05% · entry $0.0200 → $0.0100
T+1d
0.00%
call 0.00% · α -1.21%
$0.0200
settled 6mo ago
T+5d
0.00%
call 0.00% · α -0.98%
$0.0200
settled 6mo ago
T+20d
0.00%
call 0.00% · α -5.82%
$0.0200
settled 6mo ago
T+60d
-50.00%
call -50.00% · α -57.05%
$0.0100
settled 3mo ago
Price Chart
Loading chart...
Executive Summary
Radiopharm Theranostics announced completion of patient dosing in its U.S. Phase 2b trial of RAD 101 for diagnosing brain metastases, with interim data showing 90% concordance with MRI. Full data readout is expected in June 2026, and the company plans to advance into a Phase 3 pivotal trial.
Key Facts
- Final patient dosed in U.S. Phase 2b trial (NCT06777433) evaluating RAD 101 for diagnosis of recurrent brain metastases
- Interim data showed 90% concordance with MRI, the trial's primary endpoint
- Full clinical trial readout expected in June 2026
- Company plans to advance RAD 101 into U.S. Phase 3 pivotal trial
- RAD 101 received FDA Fast Track Designation for distinguishing recurrent disease from treatment effect in brain metastases
Financial Impact
Potential acceleration of regulatory pathway and future commercialization prospects for RAD 101, though no direct financial figures disclosed
pipeline progressregulatory timelineclinical development risk
Risk Factors
- Final data may not confirm interim 90% concordance rate
- Phase 3 trial design and FDA requirements not yet specified
- RAD 101 remains in development with no guarantee of approval or commercial success
Market Snapshot
Exchange
OTC
Sector
Pharmaceutical Preparations
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-044334 |
| Document: ea0286614-6k_radiopharm.htm | 0001213900-26-044334 |
| Document: 0001213900-26-044334-index-headers.html | 0001213900-26-044334 |
| Document: 0001213900-26-044334-index.html | 0001213900-26-044334 |
| Document: 0001213900-26-044334.txt | 0001213900-26-044334 |
8 reports for RDPTF
0% Hit rate @ T+60 Went positive at some point 0 of 3 best @ T+1· 0.00%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 3, 2026 20w ago | 6-K | $0.0200 $0.0100 | ▼ −50.00% | ▼ −52.50% | $0.006660 (−66.70%) |
May 6, 2026 24w ago | 3 | $0.0200 $0.0100 | ▼ −50.00% | ▼ −53.83% | $0.006660 (−66.70%) |
Apr 23, 2026 26w ago | 6-K | $0.0200 $0.0100 | ▼ −50.00% | ▼ −55.02% | $0.006660 (−66.70%) |
Apr 16, 2026 27w ago | 6-K | $0.0200 $0.0100 | ▼ −50.00% | ▼ −57.05% | $0.006660 (−66.70%) |
Apr 8, 2026 28w ago | 6-K | $0.0200 $0.0100 | ▼ −50.00% | ▼ −60.46% | $0.006660 (−66.70%) |
Apr 7, 2026 28w ago | 6-K | $0.0200 $0.0100 | ▼ −50.00% | ▼ −63.27% | $0.006660 (−66.70%) |
Apr 1, 2026 29w ago | 3 | $0.0200 $0.0100 | ▼ −50.00% | ▼ −64.16% | $0.006660 (−66.70%) |
Mar 27, 2026 30w ago | 6-K | $0.0200 $0.0200 | · 0.00% | ▼ −16.07% | $0.006660 (−66.70%) |
Showing 8 of 8
US Market Status
Market Closed — Opens Tue (16h 36m)
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers